Jane Street Group, LLC Uni Qure N.V. Call Options Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.78 - $10.12 $128,142 - $343,068	33,900 New	33,900 $167,000
Q1 2022 May 17, 2022	SELL	$14.54 - $21.5 $1.44 Million - $2.13 Million	-99,200 Reduced 59.76%	66,800 $1.21 Million
Q4 2021 Feb 15, 2022	BUY	$20.24 - $36.01 $961,399 - $1.71 Million	47,500 Added 40.08%	166,000 $3.44 Million
Q3 2021 Nov 16, 2021	SELL	$26.01 - $38.22 $1.58 Million - $2.32 Million	-60,600 Reduced 33.84%	118,500 $3.79 Million
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $3.5 Million - $4.34 Million	116,700 Added 187.02%	179,100 $5.52 Million
Q1 2021 May 18, 2021	BUY	$29.24 - $42.03 $970,768 - $1.4 Million	33,200 Added 113.7%	62,400 $2.1 Million
Q4 2020 Feb 17, 2021	BUY	$35.35 - $50.67 $707,000 - $1.01 Million	20,000 Added 217.39%	29,200 $1.06 Million
Q3 2020 Nov 17, 2020	SELL	$35.98 - $47.66 $651,238 - $862,645	-18,100 Reduced 66.3%	9,200 $339,000
Q2 2020 Aug 17, 2020	BUY	$45.06 - $67.74 $189,252 - $284,508	4,200 Added 18.18%	27,300 $1.23 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $316,079 - $584,363	7,900 Added 51.97%	23,100 $1.1 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $564,376 - $1.13 Million	15,200 New	15,200 $1.09 Million

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $793M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.